In contrast, non-V600 BRAF mutations have not been included in clinical trials with selective RAF and/or MEK inhibitors [29, 33–35]; this limitation could be due to the small proportion of patients harboring non-V600 BRAF mutations in melanoma. This evidence concerns the gene MAP2K7 and melanoma.